RTTNews BiotechCodex · 实盘不做把握 4/10不做原因:证据不足
北京时间·🕒 发布 14:25:21·⟳ 抓取 14:30:25 +5m04s·⚡ 决策 08-24 14:34:02 +3m37s·64.2 天前
GSK的Jemperli获FDA优先审评，同时Hibsago在日本获批用于慢性乙肝
事件本身偏正面，但关键交易证据不足：无法完成强制的去重、真实行情、案例库和先例event_study；且现有公开信息显示两个药品进展此前已有较强预期铺垫，短线预期差不足以在无报价条件下给ENTER。
📄 原文RTTNews Biotech↗ 原文
GSK: FDA Accepts SBLA For Jemperli With Priority Review
GSK plc (GSK,GSK.L) announced the FDA has accepted for priority review a supplemental Biologics License Application for…
不做 GSK plc（GSK.US）
正面监管进展但集团市值基数大、此前已有阳性数据和监管铺垫，且缺少真实行情与event_study，短线edge不足。
不做 AnaptysBio, Inc.（ANAB.US）
Jemperli royalty弹性存在，但本次只是优先审评受理而非批准或销售里程碑确认，且未能核实报价、流动性和先例，不给ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RTTNews称GSK的Jemperli直肠癌适应症sBLA获FDA优先审评，并披露Hibsago在日本获批。公开GSK资料显示，Jemperli该适应症已有突破性疗法认定和7月阳性中期数据，bepirovirsen日本申报、SENKU、三期阳性数据也已在2026年2月至5月披露，因此本次更多是监管路径推进。GSK集团层面市值和收入基数较大，ANAB虽有Jemperli royalty弹性但当前事件仍非批准和非即时销售确认；在缺少真实行情与先例测算的情况下不做。
消息传播链
- RTTNews转述GSK公告，披露Jemperli sBLA获FDA优先审评及Hibsago日本获批；未命中同日GSK原始新闻稿链接。
- GSK此前已披露AZUR-1中期结果达到主要目标，并称数据将提交监管机构、美国可加速审评。
- GSK此前已披露bepirovirsen三期B-Well数据，并称其在美国、欧洲、日本和中国均处于监管审评或优先审评状态。
关键理由
- Jemperli获FDA优先审评缩短审评路径，若2027年2月获批，将扩展到dMMR/MSI-H局部晚期直肠癌未治疗患者。
- Hibsago/bepirovirsen在日本获批是慢性乙肝功能性治愈方向的重要商业化进展，但此前三期阳性和日本优先审评预期已公开。
- 量级上，GSK 2025年Jemperli销售约8.61亿英镑且增长较快，但本次直肠癌sBLA尚未批准；日本慢性乙肝患者约100万人，bepirovirsen可触达市场大，但需定价、渗透率和上市节奏确认。
主要风险
- Jemperli本次仅为受理和优先审评，PDUFA在2027年2月，若FDA要求补充资料或标签范围受限，短线利好会被削弱。
- bepirovirsen日本获批的商业化价值仍取决于定价、医保准入、诊断率、用药资格和患者转化，当前无法可靠量化对GSK利润和市值的即时增量。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-13 · 影响 weakens
Jemperli本次sBLA受理前，GSK已公开披露直肠癌阳性中期数据和监管提交计划，降低突发性。
检索:GSK Jemperli rectal cancer FDA priority review prior data July 2026 bepirovirsen Japan review approval prior disclosure 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-05-28 · 影响 weakens
bepirovirsen日本监管路径和三期阳性结果此前已充分披露，本次日本获批虽正面但并非完全低扩散新信息。
检索:GSK bepirovirsen Japan SENKU NDA review B-Well data May 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次从潜在小仓观察降为不做，避免在无报价和无事件研究的情况下追监管进展。
方向:没有完成合格event_study；只能定性认为大型制药公司的审评受理通常弱于正式批准，合作方royalty票可能更有弹性但需价格和先例校准。
涨幅量级:缺少真实日线和同机制先例，不能给tp/sl或涨幅量级。
形态:未能形成可审计的见光死或持续上涨样本。
原文全文
展开原文 · 1,307 字
GSK plc (GSK,GSK.L) announced the FDA has accepted for priority review a supplemental Biologics License Application for Jemperli or dostarlimab for patients with previously untreated stage II and III mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer. The FDA has assigned a PDUFA action date of February 2027. The company noted that the application is eligible for expedited review through the National Priority Voucher program.
Separately, GSK announced that Japan's Ministry of Health, Labour and Welfare has approved Hibsago or bepirovirsen, an antisense oligonucleotide, as a functional cure for chronic hepatitis B virus infection in adult patients who have received at least 6 months of prior nucleos(t)ide analogue therapy and meet pre-defined viral markers.
At last close on LSE, GSK shares were trading at 1,918.50 pence.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
Separately, GSK announced that Japan's Ministry of Health, Labour and Welfare has approved Hibsago or bepirovirsen, an antisense oligonucleotide, as a functional cure for chronic hepatitis B virus infection in adult patients who have received at least 6 months of prior nucleos(t)ide analogue therapy and meet pre-defined viral markers.
At last close on LSE, GSK shares were trading at 1,918.50 pence.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。